Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.

Abstract

Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign blepharospasm (BEB), the main, potential long-term side effect of BoNT use is the development of immunologic resistance due to the production of neutralizing antibody to the neurotoxin after repeated injections. Xeomin(®) (incobotulinumtoxinA), a unique botulinum neurotoxin type A (BoNT/A) drug free of complexing proteins otherwise contained in all conventional BoNT/A drugs, was recently approved by US Food and Drug Administration for the treatment of cervical dystonia or blepharospasm in adults. The newly approved BoNT/A drug may overcome this limitation of previous conventional products, since it contains pure neurotoxin (150 kDa) through a manufacturing process that separates it from complexing proteins such as hemagglutinins produced by fermentation of Clostridium botulinum. Many studies have also shown that Xeomin(®) has the same efficacy and safety profile as complexing protein-containing products such as Botox(®) and is exchangeable with Botox(®) using a simple 1:1 conversion ratio. Xeomin(®) represents a new treatment option for the repeated treatment of patients with blepharospasm in that it may reduce antibody-induced therapy failure. But, long-term comparative trials in naïve patients between Xeomin(®) and conventional BoNT/A drugs are required to confirm the low immunogenicity of Xeomin(®).

• Authors: Juwan Park, Michael S Lee, Andrew R Harrison
• Journal: Clinical ophthalmology (Auckland, N.Z.) (Clin Ophthalmol) Vol. 5 Pg. 725-32 ( 2011) ISSN: 1177-5483 [Electronic] New Zealand
• PMID: 21691580 (Publication Type: Journal Article)